Trigeminal Neuralgia Research

Advancing Trigeminal Neuralgia Research:

At the core of the Trigeminal Neuralgia Association UK (TNA UK), our unwavering commitment to research and the development of new treatments for Trigeminal Neuralgia (TN) stands as a beacon of hope. It’s with this dedication that we embrace groundbreaking initiatives like the Libra Study, a symbol of our resolve to deepen our understanding of TN and to offer real hope to those affected by this debilitating condition.

The Libra Study represents a significant leap forward in TN research. Endorsed by the Medicines and Healthcare Products Regulatory Agency (MHRA) and an ethics committee, this Phase II/III multicentre clinical trial is set to evaluate the efficacy and safety of Basimglurant. By targeting the mGlu5 receptors, Basimglurant promises a new path for reducing the neural overactivity and pain associated with TN, especially for those who have found little solace in existing treatments.

In recognition of the critical role of informed support, TNA UK recently hosted a comprehensive training session in London for our helpline volunteers and regional support leaders. This session, significantly enhanced by the participation of Dr Giorgio Lambru and his team, provided a deep dive into the details of the Libra Study. Dr Lambru, a leading figure in the field and Joint Chair of our Medical Advisory Board offered invaluable insights into the trial, equipping our team with the knowledge needed to assist our members effectively. This training underscores our belief in the power of informed advocacy and support, preparing us to navigate the complexities of TN treatment options with our community.

The Libra Study’s design is a testament to the meticulous approach taken towards evaluating Basimglurant’s potential. It encompasses an initial 8-week run-in phase for dosage adjustment, a subsequent 12-week double-blind phase, and a final 52-week open-label extension phase. This comprehensive structure is aimed at rigorously assessing the treatment’s benefits and safety.

Our criteria for study participation are carefully considered, welcoming adults aged 18 to 75 diagnosed with primary or idiopathic TN. This approach is a reflection of our commitment to reaching those in urgent need of new treatment avenues. The study’s international footprint, spanning across continents, not only showcases its potential global impact but also exemplifies TNA UK’s commitment to fostering international research collaboration.

Participant support is a cornerstone of the Libra Study, with all related travel and medical expenses covered to ensure accessibility. This aligns with TNA UK’s ethos, where the well-being and support of our members are paramount.

The enthusiasm and gratitude from our community have been profound, with members appreciating the opportunity to partake in such critical research. One member eloquently shared their feelings: “A big thank you to our lovely TN association for telling me about the trial. I feel like I am able to do something for all my fellow sufferers. I am going into the trial full of optimism and hope.” These words beautifully capture the essence of our mission and the vital role of research in offering hope and enhancing the lives of those with TN.

As we forge ahead in supporting pivotal research projects like the Libra Study, the support of our members and the wider community remains invaluable. Through our collective efforts, we are poised to make significant advancements in the treatment of TN, improving the quality of life for those affected by this condition.

Together, we are not merely observers of the evolution of TN treatment; we are active contributors to a future where the challenges of Trigeminal Neuralgia can be overcome, and hope is a tangible reality for every person facing this condition.